前沿生物(688221)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688221 前沿生物

已收盘 07-25 15:00:00

{"stockData":{"symbol":"688221","market":"SH","secType":"STK","nameCN":"前沿生物","latestPrice":19.53,"timestamp":1753426800000,"preClose":20.57,"halted":0,"volume":41964257,"delay":0,"changeRate":-0.0506,"floatShares":375000000,"shares":375000000,"eps":-0.5067,"marketStatus":"已收盘","change":-1.04,"latestTime":"07-25 15:00:00","open":20.2,"high":20.57,"low":19.48,"amount":830000000,"amplitude":0.053,"askPrice":19.53,"askSize":134,"bidPrice":19.52,"bidSize":195,"shortable":0,"etf":0,"ttmEps":-0.5067,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753666200000},"marketStatusCode":5,"adr":0,"adjPreClose":20.57,"symbolType":"stock_kcb","openAndCloseTimeList":[[1753407000000,1753414200000],[1753419600000,1753426800000]],"highLimit":22.63,"lowLimit":18.51,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":374578653,"isCdr":false,"pbRate":6.67,"roa":"--","roe":"--","epsLYR":-0.54,"committee":0.815961,"marketValue":7316000000,"turnoverRate":0.112,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2025-07-28。","afterMarket":{"amount":82514.25,"volume":4225,"close":19.53,"buyVolume":0,"sellVolume":4018,"time":1753428838020,"indexStatus":"已收盘 07-25 15:30:00","preClose":20.57},"floatMarketCap":7316000000},"requestUrl":"/m/hq/s/688221","defaultTab":"news","newsList":[{"id":"2554575407","title":"7月25日前沿生物-U跌5.06%，汇添富年年泰定开混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2554575407","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554575407?lang=zh_cn&edition=full","pubTime":"2025-07-25 16:26","pubTimestamp":1753431971,"startTime":"0","endTime":"0","summary":"证券之星消息，7月25日前沿生物-U跌5.06%，收盘报19.53元，换手率11.2%，成交量41.96万手，成交额8.3亿元。重仓前沿生物-U的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为汇添富基金的汇添富年年泰定开混合A。汇添富年年泰定开混合A目前规模为0.86亿元，最新净值1.2982，较上一交易日下跌0.2%，近一年上涨5.71%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072500025968.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688221","BK0239"],"gpt_icon":0},{"id":"2552412486","title":"每周股票复盘：前沿生物（688221）使用2亿元闲置募资补充流动资金","url":"https://stock-news.laohu8.com/highlight/detail?id=2552412486","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552412486?lang=zh_cn&edition=full","pubTime":"2025-07-20 01:42","pubTimestamp":1752946930,"startTime":"0","endTime":"0","summary":"截至2025年7月18日收盘，前沿生物报收于21.39元，较上周的18.16元上涨17.79%。本周，前沿生物7月18日盘中最高价报21.79元，股价触及近一年最高点。本周关注点公司公告汇总：前沿生物药业决定使用不超过2亿元闲置首次公开发行股票募集资金暂时补充流动资金公司公告汇总前沿生物药业（南京）股份有限公司召开了第四届监事会第三次会议，审议通过了《关于使用部分闲置募集资金暂时补充流动资金的议案》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072000000424.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688221","BK0239"],"gpt_icon":0},{"id":"2552946935","title":"前沿生物：使用不超2亿元闲置募集资金暂时补充流动资金","url":"https://stock-news.laohu8.com/highlight/detail?id=2552946935","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552946935?lang=zh_cn&edition=full","pubTime":"2025-07-18 15:51","pubTimestamp":1752825114,"startTime":"0","endTime":"0","summary":"格隆汇7月18日丨前沿生物(688221.SH)公布，公司于2025年7月18日召开第四届董事会第三次会议及第四届监事会第三次会议审议通过了《关于使用部分闲置募集资金暂时补充流动资金的议案》，同意公司在确保不影响募集资金投资项目建设进度的前提下，使用不超过人民币2亿元（含2亿元）的闲置首次公开发行股票募集资金暂时补充流动资金，使用期限为公司董事会批准该议案之日起不超过12个月。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071815532297aad6fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071815532297aad6fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688221"],"gpt_icon":0},{"id":"2552910579","title":"前沿生物-U涨5.74%创近2年新高 政策催化与资金博弈共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2552910579","media":"智选洞察","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552910579?lang=zh_cn&edition=full","pubTime":"2025-07-17 13:56","pubTimestamp":1752731798,"startTime":"0","endTime":"0","summary":"前沿生物-U股价大幅上涨，最新价20.45元/股，涨幅达5.74%，创近2年新高并突破20元整数关口，成交额5.23亿元，换手率7.08%。政策催化与资金博弈共振前沿生物-U近期股价波动受政策与资金面双重驱动。商业化进程与研发突破主导估值重构长期来看，公司估值核心取决于艾可宁商业化进展及研发管线兑现能力。2023年前三季度财报显示，艾可宁收入占比达88.17%，但研发投入超营收90%，单一产品依赖与现金流压力并存。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717135649a6aefd81&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717135649a6aefd81&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688221"],"gpt_icon":0},{"id":"2551455231","title":"7月16日前沿生物-U涨9.70%，大成动态量化配置策略混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2551455231","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551455231?lang=zh_cn&edition=full","pubTime":"2025-07-16 16:12","pubTimestamp":1752653566,"startTime":"0","endTime":"0","summary":"证券之星消息，7月16日前沿生物-U涨9.70%创60日新高，收盘报19.34元，换手率10.18%，成交量38.14万手，成交额6.97亿元。重仓前沿生物-U的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金Q1季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为大成基金的大成动态量化配置策略混合A。该公募基金现任基金经理为夏高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071600025197.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688221","BK0239"],"gpt_icon":0},{"id":"2551117393","title":"前沿生物-U涨5.45% 政策催化与资金博弈共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2551117393","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551117393?lang=zh_cn&edition=full","pubTime":"2025-07-16 13:38","pubTimestamp":1752644292,"startTime":"0","endTime":"0","summary":"前沿生物-U股价大幅上涨，最新价18.59元/股，涨幅达5.45%。政策红利催化下，杠杆资金活跃度攀升，截至7月14日，近5日融资余额净增1675万元，助推股价单日振幅多次突破6%。商业化进程与研发突破主导估值重构长期来看，前沿生物-U的估值核心取决于艾可宁商业化进展及研发管线兑现能力。2023年前三季度财报显示，艾可宁收入占比达88.17%，但研发投入超营收90%，单一产品依赖与现金流压力并存。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716133818a6aca73d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716133818a6aca73d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688221","BK0239"],"gpt_icon":0},{"id":"2551119280","title":"科创成长层改革推进 券商系统升级及风险揭示书签署有序展开","url":"https://stock-news.laohu8.com/highlight/detail?id=2551119280","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551119280?lang=zh_cn&edition=full","pubTime":"2025-07-16 11:13","pubTimestamp":1752635582,"startTime":"0","endTime":"0","summary":"上交所方面正组织风险揭示书签署工作，并修订相关指南，新增《科创板科创成长层企业股票投资风险揭示书必备条款》，明确未盈利企业存在的各类投资风险。上交所下发通知要求券商完善适当性管理工作，包括完成风险揭示书签署及系统准备，给予投资者充分阅读时间，并通过多种渠道开展投资者教育。上交所将持续督促券商并开展监督检查。7月14日，上交所举办专题培训会，120家券商330余名相关负责人参会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071611164495444cb2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071611164495444cb2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","688538","688176","688322","688702","688515","01877","688277","688469","02402","688382","688192","ONC","688316","688343","688512","688327","688549","688221","688220","688256","688280","688266","688197","688387","688443","BK0239","688302","688561","688373","688165","000690.SH","09969"],"gpt_icon":0},{"id":"2551413759","title":"前沿生物-U股价下跌5.03% 医药板块资金博弈加剧波动","url":"https://stock-news.laohu8.com/highlight/detail?id=2551413759","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551413759?lang=zh_cn&edition=full","pubTime":"2025-07-15 09:56","pubTimestamp":1752544598,"startTime":"0","endTime":"0","summary":"前沿生物-U股价大幅下跌，最新价17.76元/股，跌幅5.03%。政策催化与资金博弈共振前沿生物-U近期股价波动受多重短期因素交织影响。此外，中报行情升温带动医药板块热度，但公司尚未发布业绩预告，资金短期博弈特征明显。商业化进程决定估值重构路径长期来看，前沿生物-U的核心矛盾在于艾可宁商业化进展及研发管线兑现能力。2023年前三季度财报显示，艾可宁收入占比达88.17%，但研发投入超营收90%，单一产品依赖与现金流压力并存。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715095650a6a9e4ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715095650a6a9e4ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159938","688221","BK0239"],"gpt_icon":0},{"id":"2550761170","title":"7月10日前沿生物-U涨11.48%，大成动态量化配置策略混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2550761170","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550761170?lang=zh_cn&edition=full","pubTime":"2025-07-10 16:15","pubTimestamp":1752135321,"startTime":"0","endTime":"0","summary":"证券之星消息，7月10日前沿生物-U涨11.48%创60日新高，收盘报16.12元，换手率11.01%，成交量41.24万手，成交额6.35亿元。重仓前沿生物-U的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金Q1季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为大成基金的大成动态量化配置策略混合A。该公募基金现任基金经理为夏高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071000025072.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688221"],"gpt_icon":0},{"id":"2549589341","title":"7月7日前沿生物-U涨8.02%，大成动态量化配置策略混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2549589341","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549589341?lang=zh_cn&edition=full","pubTime":"2025-07-07 16:23","pubTimestamp":1751876614,"startTime":"0","endTime":"0","summary":"证券之星消息，7月7日前沿生物-U涨8.02%创60日新高，收盘报13.87元，换手率10.37%，成交量38.84万手，成交额5.31亿元。重仓前沿生物-U的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金Q1季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为大成基金的大成动态量化配置策略混合A。该公募基金现任基金经理为夏高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070700020808.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688221","BK0239"],"gpt_icon":0},{"id":"2549308470","title":"创新药概念异动拉升 广生堂、微芯生物涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2549308470","media":"E公司","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549308470?lang=zh_cn&edition=full","pubTime":"2025-07-07 09:44","pubTimestamp":1751852651,"startTime":"0","endTime":"0","summary":"人民财讯7月7日电，创新药概念异动拉升，广生堂、微芯生物涨超10%，前沿生物、华纳药厂、泽璟制药、圣诺生物等股纷纷拉升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707094412a43ab2d8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707094412a43ab2d8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159992","688799","688321","300436","688221","688117","BK0239"],"gpt_icon":0},{"id":"2549308474","title":"前沿生物-U涨5.14% 创新药政策催化股价波动","url":"https://stock-news.laohu8.com/highlight/detail?id=2549308474","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549308474?lang=zh_cn&edition=full","pubTime":"2025-07-07 09:34","pubTimestamp":1751852072,"startTime":"0","endTime":"0","summary":"前沿生物-U股价大幅上涨，最新价13.50元/股，涨幅达5.14%。政策与资金共振引发股价波动前沿生物-U近期异动与创新药政策催化密切相关。6月30日国家医保局明确将医保数据用于研发支持，带动医药生物板块单日上涨1.01%，公司作为创新药企直接受益。2023年前三季度财报显示，艾可宁收入占比达88.17%，但研发投入占比超营收90%，商业化进程仍需加速。机构定价逻辑聚焦盈利拐点，参考同类企业摘“U”案例，2024年收入增速及管线进展将是关键观测指标。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707093640a43aadf9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707093640a43aadf9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688221","BK0239","159992"],"gpt_icon":0},{"id":"2549334400","title":"每周股票复盘：前沿生物（688221）因收盘价格涨幅达15%首登龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2549334400","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549334400?lang=zh_cn&edition=full","pubTime":"2025-07-06 02:38","pubTimestamp":1751740694,"startTime":"0","endTime":"0","summary":"截至2025年7月4日收盘，前沿生物报收于12.84元，较上周的9.83元上涨30.62%。本周，前沿生物7月4日盘中最高价报13.27元，股价触及近一年最高点。本周共计1次涨停收盘，无跌停收盘情况。本周关注点交易信息汇总：前沿生物因收盘价格涨幅达到15%首次登上龙虎榜交易信息汇总沪深交易所2025年7月1日公布的交易公开信息显示，前沿生物因有价格涨跌幅限制的日收盘价格涨幅达到15%的前五只证券登上龙虎榜。此次是近5个交易日内第1次上榜。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070600000272.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688221"],"gpt_icon":0},{"id":"2548365808","title":"7月4日前沿生物-U涨8.26%，大成动态量化配置策略混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2548365808","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548365808?lang=zh_cn&edition=full","pubTime":"2025-07-04 16:23","pubTimestamp":1751617420,"startTime":"0","endTime":"0","summary":"证券之星消息，7月4日前沿生物-U涨8.26%创60日新高，收盘报12.84元，换手率7.81%，成交量29.27万手，成交额3.69亿元。重仓前沿生物-U的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金Q1季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为大成基金的大成动态量化配置策略混合A。该公募基金现任基金经理为夏高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070400025474.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688221","BK0239"],"gpt_icon":0},{"id":"2548072848","title":"7月1日前沿生物（688221）龙虎榜数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2548072848","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548072848?lang=zh_cn&edition=full","pubTime":"2025-07-01 17:23","pubTimestamp":1751361799,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2025年7月1日公布的交易公开信息显示，前沿生物因有价格涨跌幅限制的日收盘价格涨幅达到15%的前五只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2025年7月1日收盘，前沿生物报收于12.05元，上涨20.02%，涨停，换手率6.36%，成交量23.81万手，成交额2.74亿元。从龙虎榜数据可以发现和研究机构、游资和散户的资金动向。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070100029014.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688221"],"gpt_icon":0},{"id":"2548822078","title":"7月1日前沿生物（688221）涨停分析：核心产品增长、研发升级驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2548822078","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548822078?lang=zh_cn&edition=full","pubTime":"2025-07-01 15:26","pubTimestamp":1751354784,"startTime":"0","endTime":"0","summary":"证券之星消息，前沿生物7月1日涨停收盘，收盘价12.05元。今日前沿生物涨停的可能因素有：1、核心产品艾可宁商业化能力持续强化，2024年收入同比增长13.32%至1.29亿元，覆盖全国300余家医院并新增5项指南推荐适应症；2、研发管线战略升级，小核酸药物FB7013进入IND阶段，形成长效抗HIV、小核酸及高端仿制药三线布局，技术壁垒提升；3、2025年一季度营收同比增长14.93%，归母净利润亏损同比收窄20.80%，经营效率改善信号显著。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070100020491.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688221"],"gpt_icon":0},{"id":"2548302198","title":"异动快报：前沿生物-U（688221）7月1日13点24分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2548302198","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548302198?lang=zh_cn&edition=full","pubTime":"2025-07-01 13:25","pubTimestamp":1751347524,"startTime":"0","endTime":"0","summary":"证券之星7月1日盘中消息，13点24分前沿生物-U触及涨停板。目前价格12.05，上涨20.02%。其所属行业化学制药目前上涨。领涨股为山河药辅。该股为创新药，医药，疫苗概念热股，当日创新药概念上涨2.2%，医药概念上涨1.78%，疫苗概念上涨0.45%。7月1日的资金流向数据方面，主力资金净流入288.47万元，占总成交额12.9%，游资资金净流出57.7万元，占总成交额2.58%，散户资金净流出230.77万元，占总成交额10.32%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070100019316.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688221"],"gpt_icon":0},{"id":"2546724853","title":"销售费用多年居高不下 上交所五问前沿生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2546724853","media":"中国经营网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546724853?lang=zh_cn&edition=full","pubTime":"2025-06-28 04:54","pubTimestamp":1751057640,"startTime":"0","endTime":"0","summary":"针对上交所2024年年报问询函，6月21日前沿生物进行了回复。同时，销售费用占营收的比例超过六成加剧了前沿生物的亏损。销售费用高企2024年，前沿生物销售费用为8634.4万元，同比增长33.3%。2018年，在艾可宁上市初期，销售工作处于起步阶段，销售收入规模整体较小，前沿生物销售费用是营业收入的4倍。截至目前，艾可宁仍是前沿生物的主要收入来源。创新药毛利率明显偏低前沿生物连续多年处于亏损状态。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506280455409791cf9e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506280455409791cf9e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688221","BK0239","688076"],"gpt_icon":0},{"id":"2546757200","title":"前沿生物-U06月26日遭主力抛售629.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2546757200","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546757200?lang=zh_cn&edition=full","pubTime":"2025-06-26 15:21","pubTimestamp":1750922504,"startTime":"0","endTime":"0","summary":"06月26日, 前沿生物-U股价跌2.69%，报收9.78元，成交金额3695.4万元，换手率1.00%，振幅3.18%，量比1.28。前沿生物-U今日主力资金净流出629.0万元，连续3日净流出，上一交易日主力净流出28.3万元。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为50.00%，平均跌幅为1.61%。该股近5个交易日上涨0.72%，主力资金累计净流出570.3万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出1697.7万元，其中净流出天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626170345a4bedec3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626170345a4bedec3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688221","BK0239"],"gpt_icon":0},{"id":"2545491630","title":"前沿生物：2024年营收1.29亿元，核心产品艾可宁收入增4.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2545491630","media":"公司公告","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545491630?lang=zh_cn&edition=full","pubTime":"2025-06-23 16:47","pubTimestamp":1750668446,"startTime":"0","endTime":"0","summary":"前沿生物公告，2024年实现营业收入1.29亿元，同比增长13.32%。核心产品艾可宁?销量27.14万支，销售收入1.14亿元，同比增加4.05%，毛利率28.99%。公司募投项目制剂生产基地已启用，就客户销售、生产模式及产能规划等回复监管问询，表明不存在经销商压货或期后退货情形，并对资产减值风险进行评估。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623165109a4b88dcb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623165109a4b88dcb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688221"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1753544320635,"stockEarnings":[{"period":"1week","weight":-0.087},{"period":"1month","weight":0.9433},{"period":"3month","weight":1.2923},{"period":"6month","weight":1.0196},{"period":"1year","weight":2.807},{"period":"ytd","weight":1.001}],"compareEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":0.0398},{"period":"3month","weight":0.0906},{"period":"6month","weight":0.1048},{"period":"1year","weight":0.2449},{"period":"ytd","weight":0.0722}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"前沿生物药业(南京)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"11392人(较上一季度减少4.10%)","perCapita":"32880股","listingDate":"2020-10-28","address":"江苏省南京市江宁区科学园乾德路5号7号楼(紫金方山)","registeredCapital":"37457万元","survey":"　　前沿生物药业(南京)股份有限公司的主营业务是创新药物的研发、生产和销售。公司的主要产品是艾可宁®。公司通过了国家第六批专精特新小巨人企业认定、国家高新技术企业复核认定。","listedPrice":20.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"前沿生物(688221)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供前沿生物(688221)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"前沿生物,688221,前沿生物股票,前沿生物股票老虎,前沿生物股票老虎国际,前沿生物行情,前沿生物股票行情,前沿生物股价,前沿生物股市,前沿生物股票价格,前沿生物股票交易,前沿生物股票购买,前沿生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"前沿生物(688221)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供前沿生物(688221)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}